NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Sentiment,

We know from the SNO data that a total of 28.2% of all 331 patients, or 93, made it past 36 months.
I'm pretty sure it's 94 at this time. See OS curve 2018.

91 patients made it past 36 months and you see 3 censors between 35 and 36 months.
Of 2 of these 3 patients there was recently news available on the web.(good news)

Survival at 3 years for the unmethylated = 162 patients is 14.3%.
14.3% of 162 =23.16.

23 unmethylated patients made it past 36 months and you see 2 LTFU unmethylated censors around 9 months on the last 2018 OS unmethylated curve.
https://pbs.twimg.com/media/DsOGDz_W0AAeYpL.jpg

We know from our analysis (and your great work) that 8 out of 23 unmethylated patients come from the first 223 patients.

15 of these 23 unmethylated patients come from the last group of 108.

It is also my guess that NO CONTROL meth- patients lived to 36 months.

So in that case: 223 – 38 unknown= 185 patients (methylated and unmethylated)(placebo and treatment).

2/3 treatment = 123 patients

55.4% of 123 unmethylated= 68 unmethylated treatment patients.

8 of these 68 made it to 36 months = 11.7% (if you believe that all 8 patients are from the treatment group= DCVAX-L from the start.)

In that last group of 108 patients we have 46 unmethylated patients (83 treatment X 55.4% = 46 unmethylated)

15 of these last 46 unmethylated patients made it to 36 months =32.6% (if you believe that all 15 patients are from the treatment group= DCVAX-L from the start.)

32.6% against 11.7%

I think this is additional evidence that a change took place when the Germans came on board. In the meantime I found more evidence pointing in that direction (data, German comment, reaction Germans on the publication 2017, story Australian GBM patient etc.)

Read this:

Herstellung des Immuntherapeutikums DCVax®-L für Gehirntumorpatienten.

Das Fraunhofer IZI produziert und optimiert ein klinisches Prüfpräparat in Europa, dessen Wirksamkeit im Rahmen einer klinischen Studie der Phase III überprüft wird. Das Immuntherapeutikum DCVax®-L wurde vom amerikanischen Biotechnologieunternehmen Northwest Biotherapeutics Inc. in den USA bereits erfolgreich in klinischen Studien eingesetzt. Dieses Arzneimittel für neuartige Therapien (ATMP) basiert auf autologen Dendritischen Zellen zur Behandlung von Glioblastomen, einer besonders aggressiven Form von Hirntumoren
http://publica.fraunhofer.de/eprints/urn_nbn_de_0011-n-4066911.pdf

So

Das Fraunhofer IZI produziert und optimiert ein klinisches Prüfpräparat in Europa

Google Translate:
The Fraunhofer IZI produces and optimizes a clinical investigational drug in Europe

If possible, try to read the German version of their reports. I think you can learn more from it.